Citations (19)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Liqi Li, Hu Huang, Mingjie Zhu & Junqiang Wu. (2021) Identification of Hub Genes and Pathways of Triple Negative Breast Cancer by Expression Profiles Analysis. Cancer Management and Research 13, pages 2095-2104.
Read now
Read now
Mohammad Hojjat-Farsangi. (2016) Targeting non-receptor tyrosine kinases using small molecule inhibitors: an overview of recent advances. Journal of Drug Targeting 24:3, pages 192-211.
Read now
Read now
Peter Norman. (2014) Inducible tyrosine kinase inhibitors: a review of the patent literature (2010 – 2013). Expert Opinion on Therapeutic Patents 24:9, pages 979-991.
Read now
Read now
Jean-Damien Charrier & Ronald MA Knegtel. (2013) Advances in the design of ITK inhibitors. Expert Opinion on Drug Discovery 8:4, pages 369-381.
Read now
Read now
Articles from other publishers (15)
Avery August. (2023) Degrading the signal amplifier: ITK as a target for targeted protein degradation. Cell Chemical Biology 30:4, pages 337-339.
Crossref
Crossref
Baishan Jiang, David M. Weinstock, Katherine A. Donovan, Hong-Wei Sun, Ashley Wolfe, Sam Amaka, Nicholas L. Donaldson, Gongwei Wu, Yuan Jiang, Ryan A. Wilcox, Eric S. Fischer, Nathanael S. Gray & Wenchao Wu. (2023) ITK degradation to block T cell receptor signaling and overcome therapeutic resistance in T cell lymphomas. Cell Chemical Biology 30:4, pages 383-393.e6.
Crossref
Crossref
Kristina S. Lechner, Markus F. Neurath & Benno Weigmann. (2020) Role of the IL-2 inducible tyrosine kinase ITK and its inhibitors in disease pathogenesis. Journal of Molecular Medicine 98:10, pages 1385-1395.
Crossref
Crossref
Marian C. Bryan & Naomi S. Rajapaksa. (2018) Kinase Inhibitors for the Treatment of Immunological Disorders: Recent Advances. Journal of Medicinal Chemistry 61:20, pages 9030-9058.
Crossref
Crossref
Craig C. Carson, Stergios J. Moschos, Sharon N. Edmiston, David B. Darr, Nana Nikolaishvili-Feinberg, Pamela A. Groben, Xin Zhou, Pei Fen Kuan, Shaily Pandey, Keefe T. Chan, Jamie L. Jordan, Honglin Hao, Jill S. Frank, Dennis A. Hopkinson, David C. Gibbs, Virginia D. Alldredge, Eloise Parrish, Sara C. Hanna, Paula Berkowitz, David S. Rubenstein, C. Ryan Miller, James E. Bear, David W. Ollila, Norman E. Sharpless, Kathleen Conway & Nancy E. Thomas. (2015) IL2 Inducible T-cell Kinase, a Novel Therapeutic Target in Melanoma. Clinical Cancer Research 21:9, pages 2167-2176.
Crossref
Crossref
Dramane Lainé, Matthew Lucas, Francisco Lopez-Tapia & Stephen Lynch. 2013. Medicinal Chemistry Approaches to Personalized Medicine. Medicinal Chemistry Approaches to Personalized Medicine
255
288
.
Jinghui Wang, Feng Li, Yan Li, Yinfeng Yang, Bin Wang, Shuwei Zhang & Ling Yang. (2013) Insight into the structural requirements of benzimidazole derivatives as interleukin-2 inducible t-cell kinase inhibitors by computational explorations. International Journal of Quantum Chemistry 113:21, pages 2385-2396.
Crossref
Crossref
Jason A. DubovskyKyle A. Beckwith, Gayathri NatarajanJennifer A. WoyachSamantha JaglowskiYiming ZhongJoshua D. HesslerTa-Ming LiuBetty Y. ChangKarilyn M. LarkinMatthew R. StefanovskiDanielle L. ChappellFrank W. FrissoraLisa L. SmithKelly A. SmuckerJoseph M. FlynnJeffrey A. JonesLeslie A. AndritsosKami MaddocksAmy M. LehmanRichard FurmanJeff Sharman, Anjali MishraMichael A. CaligiuriAbhay R. Satoskar, Joseph J. BuggyNatarajan MuthusamyAmy J. Johnson & John C. Byrd. (2013) Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood 122:15, pages 2539-2549.
Crossref
Crossref
Catherine M. AlderMartin AmblerAmanda J. CampbellAurelie C. ChampignyAngela M. DeakinJohn D. HarlingCarol A. HarrisTim LongstaffSean LynnAoife C. MaxwellChris J. MooneyCallum ScullionOnkar M. P. SinghIan E. D. SmithDonald O. SomersChristopher J. TameGareth WayneCaroline WilsonJames M. Woolven. (2013) Identification of a Novel and Selective Series of Itk Inhibitors via a Template-Hopping Strategy. ACS Medicinal Chemistry Letters 4:10, pages 948-952.
Crossref
Crossref
Chandrasekaran Meganathan, Sugunadevi Sakkiah, Yuno Lee, Jayavelu Venkat Narayanan & Keun Woo Lee. (2012) Discovery of potent inhibitors for interleukin-2-inducible T-cell kinase: structure-based virtual screening and molecular dynamics simulation approaches. Journal of Molecular Modeling 19:2, pages 715-726.
Crossref
Crossref
Arun Kannan, Weishan Huang, Fei Huang & Avery August. (2012) Signal transduction via the T cell antigen receptor in naïve and effector/memory T cells. The International Journal of Biochemistry & Cell Biology 44:12, pages 2129-2134.
Crossref
Crossref
Qian Qi, Weishan Huang, Yuting Bai, Gabriel Balmus, Robert S. Weiss & Avery August. (2012) A Unique Role for ITK in Survival of Invariant NKT Cells Associated with the p53-Dependent Pathway in Mice. The Journal of Immunology 188:8, pages 3611-3619.
Crossref
Crossref
Qian Qi, Arun Kumar Kannan & Avery August. (2011) Structure and function of Tec family kinase Itk. BioMolecular Concepts 2:3, pages 223-232.
Crossref
Crossref
Alamdar Hussain, Liang Yu, Rani Faryal, Dara K. Mohammad, Abdalla J. Mohamed & C. I. Edvard Smith. (2011) TEC family kinases in health and disease – loss‐of‐function of BTK and ITK and the gain‐of‐function fusions ITK–SYK and BTK–SYK. The FEBS Journal 278:12, pages 2001-2010.
Crossref
Crossref
Jean-Damien CharrierAndrew MillerDavid P. KayGuy BrenchleyHeather C. TwinPhilip N. CollierSharn RamayaShazia B. KeilySteven J. DurrantRonald M. A. KnegtelAdam J. TannerKieron BrownAdam P. CurnockJuan-Miguel Jimenez. (2011) Discovery and Structure−Activity Relationship of 3-Aminopyrid-2-ones as Potent and Selective Interleukin-2 Inducible T-Cell Kinase (Itk) Inhibitors. Journal of Medicinal Chemistry 54:7, pages 2341-2350.
Crossref
Crossref